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Childhood atopic eczema consensus document
A I Manjra, P du Plessis, R Weiss, C M Motala, P C Potter, N Raboobee, N Ndlova, M Davis,  E G Weinberg (Members of the
South African Childhood Atopic Eczema Working Group, a subcommittee of the Allergy Society of South Africa) 
Background and prevalence
The prevalence of atopic eczema (AE) has risen over the past
few decades.
1,2
There is a paucity of data on the prevalence of AE
in South Africa.  The ISAAC phase 1 study2 reported a
prevalence of 5 - 10% in Cape Town schoolchildren.  A recent
study by Todd et al.3 conducted among Xhosa children
demonstrated a point prevalence (dermatologist-diagnosed) of
0.7%, 1.1% and 3.7% in rural, peri-urban and urban settings
respectively. AE is therefore very rare in Xhosa children in rural
settlements and a clear urban/rural gradient exists for the
occurrence of AE in black children.  AE is frequently
undertreated despite severely affecting the quality of life of
patients and their families.  AE also commonly predates the
development of allergic rhinitis and asthma.
Nomenclature and classification of
eczema
In May 2004 the World Allergy Organization (WAO) published a
new report by its Nomenclature Review Committee.1 The new
WAO nomenclature is an update of the EAACI document
defining terminology for skin allergies.1
The WAO recommends that the umbrella term for local
inflammation of the skin should be ‘dermatitis’.  The term
‘eczema’ describes an aggregation of several skin diseases with
clinical characteristics in common, involving a genetically
determined skin barrier defect.
In children and young adults with an atopic constitution, the
underlying inflammation is dominated by an immunoglobulin E 
(IgE) antibody-associated reaction allowing the term AE to be
applied.  This term should replace the term ‘atopic dermatitis’.
The diagnosis of AE cannot be reached without an IgE antibody
determination or skin test.  In other eczema cases where the
inflammation is not associated with elevated IgE antibody, these
patients are considered to have non-atopic eczema (Fig. 1).
AE is more common in preschool children, with a prevalence
of 45 - 64%,
4
but in adults the incidence can be as high as 40%.
Children with AE have a greater risk of developing asthma
(approximately 30%) than children with non-atopic eczema.
They also have associated food allergies and IgE-induced
urticaria. Therefore the interventional, prognostic and co-
morbidity implications for patients with AE are different from
the implications for those with non-atopic eczema, where
management is largely directed to management of the skin itself.
Diagnosis of AE
Fig. 1 in conjunction with Table I will help in the diagnosis and
assessment of the severity of AE.
Pathogenesis
The pathogenesis of eczema is a complex interplay of numerous
elements including immune, genetic, infection and neuroendo-
crine factors and their interaction with the environment.
Important immunological pathways include Langerhans cells,
eosinophils, T-cells, mast cells, basophils, Fc epsilon receptors
and IgE.  Phosphodiesterase abnormalities and cyclic nucleotide
dysregulation lead to reduced cyclic AMP modulation, and
increased inflammatory activity is also present.
Corresponding author: A I Manjra (manjra@mweb.co.za)
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Fig 1. The new World Allergy Organization (WAO) classification of eczema/dermatitis (2004).
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Furthermore, neural mediators such as substance P,
acetylcholine, calcitonin, gene-related peptide and neurokinin
A are also important.  Decreased barrier function leads to
increased transepidermal loss, decreased water content of the
stratum corneum, increased permeability to hydrophilic
substances, decreased ceramides in the skin and decreased
barrier to infectious agents.
Provoking factors for eczema exacerbations include the
following: (i) microbial colonisation (Staphylococcus aureus); (ii)
stress; (iii) barrier disruption; (iv) environmental exposure; (v)
contact, inhalant and ingestant allergens; (vi) sweating; (vii)
pollutants; (viii) sensory irritants (wool); (ix) chemical irritants;
and (x) maternal ingestants (in breast-milk).
Implications for identifiable allergic
pathogenetic factors
Since a number of environmental factors are known to trigger
eczema flare-ups, these must be identified and avoided.  In
those patients with AE specific sensitivity to an environmental
factor can be confirmed and specific avoidance implemented.
Nonspecific irritants and other factors appear to aggravate
both the atopic and non-atopic forms of eczema (e.g. wool,
chemicals in soaps, etc.).
In patients with AE who are sensitive to house-dust mites,
intensive house-dust mite avoidance measures, including hot
washing of the bedding at 60oC and mite-impermeable mattress
covers and bedding covers play an important role in reducing
the severity of the symptoms.
2
In young patients with specific IgE to foods, the significance
in a given patient must be assessed either from the level of
specific IgE or the size of the skin-prick wheal.  Certain cut-off
values have a 95% predictive value for clinical sensitivity to
such foods.
5
Prevention of AE – evidence
The cumulative evidence of studies has proven that inter-
vention is worthwhile in high-risk families. There is now
sufficient evidence that exclusive breast-feeding of high-risk
infants for at least 4 months prevents the development of AE.
6
If mothers are unable to breast-feed, a hypoallergenic
extensively hydrolysed formula is given to the infant (e.g.
Alfare, Nutramigen). If this is not possible a partially
hydrolysed formula such as Nan-HA may be tried.
There is no good evidence that the automatic substitution of
breast-milk with soya formula will prevent allergic diseases,
although soya milk may be used as an alternative in infants
who have confirmed cow’s milk allergy.
7
Food testing in established AE
The importance of food allergy in the development and
aggravation of the symptoms of atopic dermatitis in infants
and young children is now well established.  In contrast, food
allergy is much less common and appears to play a far less
important role in teenagers and adults with atopic dermatitis.
Food allergy in the general paediatric population has a
prevalence of 4 - 5%, whereas up to 80% of infants with atopic
dermatitis will have positive food allergy tests.
8
Because of the high prevalence of food allergy in infants and
young children with atopic dermatitis, testing for food allergy
is an essential part of the management of the infant.
Paediatric food allergy screening
IgE testing is cost-effective. The foods most commonly
implicated in allergy in young infants are egg, milk, peanut,
wheat, fish and soya.  These can be screened by performing a
Fx5e CAP paediatric screening test and if positive, specific IgE
CAP RAST for the individual allergens can be requested.
Skin-prick tests
Skin-prick tests (SPTs) are inexpensive and provide quick
results. SPTs have been found to be a highly sensitive but
moderately specific indicator of an immediate reaction to food.
They require co-operation in young children. A wheal of
greater than 3 mm with a visible red flare constitutes a positive
result provided that the saline control is non-reactive and that
the histamine-positive control gives at least a 3 mm wheal-and-
flare response.
The predictive values of SPTs have been published and can
be used as a guide to determine sensitivity.
Table I. Assessment and stepwise diagnosis of atopic eczema
Step 1 Step 2 Step 3 Step 4
Can do as necessary
Must have: Need 3 or more: (not essential): Classify:
Pruritus • Flexural eczema Evaluate and manage: Mild
• Previous flexural eczema • Rhinitis
• Dry skin • Asthma Moderate
• Other atopic disease • Food allergy
• Onset before age 2 • Environmental allergy Severe
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CAP RAST blood tests
The concept of a cut-off value above which a test has a very
high positive predictive value for allergy is not entirely clear.
Using specific IgE values generated by the Pharmacia CAP
system, Sampson and Ho
9
have correlated the results of IgE
values with the results of double-blinded food challenges.
Specific IgE values giving positive predictive values of at least
95% were egg (6 kµ/l), milk (32 kµ/l), peanuts (15 kµ/l) and
fish (20 kµ/l). Importantly, the negative predictive value of
both blood and skin tests is greater than 95%.
Other tests
‘Atopy patch testing’ is being explored as an alternative test for
detecting food sensitivities.
10
Its role is still currently regarded
as experimental.
Management
Management of atopic dermatitis should comprise: (i) general
measures – avoidance of trigger factors; (ii) adjuvant measures;
and (iii) anti-inflammatory therapy.
Table II is a summary of the management of AE.
Role of general measures
There is consensus that the following may be beneficial in
management of AD: (i) avoid overheating and external
irritants; (ii) keep the skin covered with clothing as this may
reduce exposure to irritants and trauma from scratching; (iii)
avoid skin care products that cause irritation, e.g. astringents
and soaps; (iv) avoid wool clothing (or fabrics with rough
texture or occlusive properties) – cotton is preferable; and (v)
advise on hobbies, occupational exposure and potentially
harmful habits, e.g. excessive hand washing.
Role of bathing 
Further study is required to determine the efficacy of various
cleansers used in bathing, the role of bathing as a steroid-
sparing modality, and the optimal duration of bathing.
Emollients applied during or after bathing provide a surface
lipid film retarding evaporative water loss from the epidermis.
The current recommendations are:
11,12
(i) regular bathing to
hydrate the skin and debride crust – useful for most patients
for both cleansing and hydrating the skin; (ii) bathe once daily
for several minutes in warm (not hot) water; (iii) use a
moisturising cleanser; (iv) avoid antibacterial cleansers (may
lead to bacterial resistance); (v) after bathing, pat dry; and (vi)
emollients should be applied immediately after bathing.
Role of emollients
Skin dryness is a very common feature of AE and is a
diagnostic criterion for the disease. Emollients are universally
recommended as first-line therapy; however, despite this there
is a paucity of studies to justify their use, and in fact the quality
and quantity of evidence is inversely proportional to the
frequency of use.
13,14
437
June 2005, Vol. 95, No. 6  SAMJ
Table II. Treatment and management of atopic eczema
Clear Mild Moderate Severe
Basic treatment Emollients Emollients Emollients Emollient
Maintenance TCI (pimecrolimus) TCI (pimecrolimus) Consider referral
Mild TCS Mild/moderate TCS Moderate/potent TCS
Consider treatment as for
flare
Flare As above Temporarily replace Consider referral
maintenance treatment with Cyclosporine
moderate/potent TCS Azathioprine
Phototherapy
Oral steroids
Methotrexate
Adjuvant treatment Antibiotics Antibiotics Antibiotics
(optional, not Search for and avoid Antihistamines Antihistamines
routinely needed) trigger factors Search for and avoid Search for and avoid 
trigger factors trigger factors
Always Herpetic infections Herpetic infections Herpetic infections Herpetic infections
treat Bacterial infections Bacterial infections Bacterial infections Bacterial infections
TCI = topical calcineurin inhibitors (pimecrolimus (Elidel)); TCS: topical cortisone preparations (see Table III for guideline to potency).
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The consequences of dry skin include: (i) inflammation;
15
(ii)
loss of suppleness leading to fissuring; (iii) impaired barrier
function; and (iv) increased adherence of S. aureus.
Use of emollients
Emollients are effective as first-line agents and may be steroid-
sparing.
Ointments and creams provide better barrier function than
lotions. In general, oilier preparations are better emollients but
these may be too messy for routine use. Different preparations
may be needed for the face and body.  Patients should be
allowed to decide on the most suitable emollient for their skin,
i.e. an emollient that is effective and cosmetically acceptable.
Emollients must be applied frequently.  The maximum
duration of any emollient is 6 hours.  They should be applied
regularly, at least twice during the day, even if there are no
symptoms, and after swimming or bathing.  This cleanses the
skin and reduces the bacterial load.  Best results are seen if
emollients and medications are applied within 3 minutes of
bathing to retain hydration.16 Sufficient quantities must be
prescribed, viz. 250 g/week for children and 500 g/week for
adults for the whole body.
Adverse effects
No adverse effects are reported other than mild transient
burning with oil-in-water emollients17 or with urea-containing
products.
18
Topical steroids
Although topical steroids have been the cornerstone of AE
treatment for the last 40 years, there is surprisingly little
consensus on the most effective way in which to use them.
Steroid phobia, i.e. an unwillingness to use topical steroids
because of exaggerated perception of side-effects, has emerged
as a significant problem, especially in affluent countries.
Caregivers should reinforce the positive benefits of topical
steroids.
In the most extensive systematic review of treatments for
AE,
14
it was found that an analysis of randomised controlled
trials confirmed a significant benefit of topical steroids over
placebo. There are many different strengths of steroids and
formulations on the market; however it is difficult to assess the
best products owing to inadequate supporting evidence.
It is possible to make a few general claims for topical
steroids: (i) there is no evidence that antibiotic/corticosteroid
combinations are more effective than steroids alone; (ii) the
type of vehicle used for a topical steroid may enhance its
efficacy; (iii) patients prefer cosmetically acceptable topical
steroid creams; (iv) there is no evidence to support the use of
once-daily versus twice-daily topical corticosteroid
administration; (v) there is no evidence to suggest that skin
thinning is a problem with correct use of topical
corticosteroids; and (vi) dilution of topical steroids does not
necessarily reduce adverse effects – this could affect stability,
compatibility and microbiological purity.
Intermittent use of mild to mid-potency topical steroids in
conjunction with emollients has been standard disease
management (Table III).
16
Reactive treatment with more potent
steroids may be needed for relief of acute flares. Short-burst
treatment with a potent topical steroid (0.1% betamethasone-
valerate) had better results than long term use of 1%
hydrocortisone  in an 18-week trial.
19
Recommendations for use of topical steroid management in
AE are as follows.20
1. Most AE requires initial use of mid-strength steroids.
However, 1% hydrocortisone is advised in children with mild
to moderate eczema unless under specialist care.
2. Most topical steroids are applied either once or twice daily
(as specified by the manufacturers) to induce remission.
Thereafter intermittent use, typically twice weekly, may be
continued to maintain control. The least potent preparation
that adequately controls the disease process should be
selected.11
3. High-potency topical steroids may be needed for short
bursts in areas of lichenification or thick skin.
4. The vehicle base influences the potency, with ointments
more potent than creams. Wet wraps and occlusion increase
potency and less potent topical steroids should be used when
this modality is used.
5. As inflammation subsides, use less topical steroids and
more moisturiser.
6. Mid-strength topical steroids used immediately after
bathing can be used intermittently in conjunction with
emollients.21
Adverse events
These are well documented, and occur primarily when applied
continuously especially on delicate skin areas such as the face,
neck and skin folds.
Cutaneous effects are skin atrophy, telangiectasia,
hypopigmentation, steroid acne, increased hair growth, and
Table III. Table of potency of topical cortisone preparations
Mild strength Moderate strength Potent strength
Procutan Advantan Dermovate
Mylocort Elocon Diprolene
Stopitch Locoid Nerisone Forte
Synalar
Betnovate
Persivate
Diprosone
Nerisone
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rosacea-like reactions. Systemic effects are uncommon such as
suppression of the hypothalamic-pituitary-adrenal (HPA) axis,
growth retardation, and increased risk of glaucoma, cataract
and Cushing’s syndrome.
Antihistamines in atopic dermatitis
Evidence-based studies on the effectiveness of oral
antihistamines in the management of atopic dermatitis are
conflicting and their value is often disputed.  First-generation
sedating antihistamines have traditionally been prescribed for
the treatment of pruritus and for sedation.11
Systemic antihistamines act primarily by blocking the H1
receptors in the dermis and thereby ameliorate histamine-
induced pruritus. However, histamines are only one of many
agents that produce pruritus and  many patients may receive
only minimal benefit from antihistamines.22-24
It has been found that even if there is benefit to some
individual patients, the effectiveness of antihistamines is often
short lived because of tachyphylaxis; increasing doses may be
required and antihistamines are therefore contraindicated for
long-term therapy.12,25,26 They may be useful adjuncts to therapy
during acute flares especially for sedation and for their
anxiolytic effects.23,27
As pruritus is worse at night the sedating antihistamines
may be used at bedtime.
Topical antihistamine applications may be of use for very
short periods but should not be used chronically as they may
cause sensitisation and should be avoided if possible.23
New non-steroidal topical immuno-
modulators (calcineurin inhibitors)
New therapies such as the topical calcineurin inhibitor
pimecrolimus represent major advances in the management of
AE.  They complement existing treatment options and also
overcome some of the drawbacks of topical steroid therapy.
They have a specific mechanism of action, inhibiting
inflammatory cytokine transcription in activated T-cells and
other inflammatory cells through inhibition of calcineurin.28,29
They selectively target the inflammatory cells involved in AE
without suppressing the Langerhans cells. They are therefore
extremely safe and can be used for long-term treatment and
prevention of AE.  
Pimecrolimus cream has been approved in South Africa for
the treatment of mild to moderate AE in children 2 years and
older.  It is indicated for acute as well as long-term
management of mild to moderate AE. It can alleviate the
symptoms and prevent flare progression in children.
Pimecrolimus  can be used safely on sensitive areas
including the face, neck and flexures. It is also indicated in
children where the parents may have reservations about using
topical steroids (steroid phobia). Kapp et al.30 have shown that
pimecrolimus can be used safely in infants as young as 3 years
of age.
The results of short- and long-term clinical trials on
pimecrolimus demonstrate a rapid and sustained effect in
controlling pruritus, which is the primary complaint of patients
with AE.
Patients treated with pimecrolimus should be counselled on
the use of appropriate sun protection, including the application
of sunscreen.  This is because of concern regarding the
potential for development of cutaneous malignancy.
Tacrolimus, a topical immunomodulator, is not available in
South Africa at present.
Use of phototherapy, tar and systemic
immunomodulators
Phototherapy
The following forms of phototherapy have been used in the
management of AE:31 (i) conventional UVA/UVB combination
therapy; (ii) UVA1 therapy; (iii) photochemotherapy with
methoxsalen plus UVA (PUVA); and (iv) narrow-band UVB
(312 nm).
High-dose UVA1 has strong immunomodulating properties.
However, there is ongoing discussion on the risk of long-term
carcinogenicity associated with its use.
PUVA therapy may be associated with severe side-effects,
including the development of cutaneous neoplasms.
Tar preparations
In selected patients tar preparations may be effective,
administered topically or in the bathtub.11 The cosmetic
disadvantages of coal tar make it unacceptable to many
patients and may affect compliance.32 There are few scientific
studies focusing on the clinical efficacy of tar in the treatment
of AE.33
Systemic immunomodulators
Oral immunomodulators have been used predominantly for
severe AE, including ciclosporin, azathioprine and myco-
phenolic acid, among others.32
Ciclosporin
Ciclosporin is effective in the treatment of severe AE, but its
usefulness may be limited by side-effects.32 Trials have
demonstrated prompt relief of symptoms with rapid relapse
after cessation of therapy.  Long-term maintenance therapy
provides satisfactory freedom from remissions. In one group of
children, short-course ciclosporin treatment given in 12-week
cycles, with at least 7 days between each course, resulted in a
lower cumulative dose of ciclosporin compared with children
on continuous therapy.33
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Interferon-gamma
Three randomised controlled clinical trials reported that
interferon-gamma provided significant relief from AD
symptoms.  However, evidence is limited to a subset of
patients and there was a high overall rate of side-effects.34-36
Systemic corticosteroids
Systemic corticosteroids are known to be effective in the short-
term treatment of AD, but no evidence exists to support their
use.  They are not routinely recommended as rebound flaring
and long-term side-effects limit their use.32 Their use should be
confined to specialists.
Azathioprine
A randomised, double-blind, placebo-controlled trial37
examined the use of azathioprine 2.5 mg/kg per day in the
treatment of AD, but conclusions were limited by a high drop-
out rate.  In another study,38 azathioprine was shown to be
effective but potential toxicities limited its use.
Mycophenolate mofetil and intravenous immunoglobulin
Conflicting data exist on the efficacy of mycophenolate mofetil
and intravenous immunoglobulin.11
Others
There is insufficient evidence to support the role of leukotriene
inhibitors, thymopentin (TP-5), allergen-antibody complexes of
house-dust mites, desensitisation injections, theophylline, and
papaverine in the treatment of AE.32
There is recent evidence that probiotics with Lactobacillus
rhamnosis (ATCC 53103) administered to at-risk infants in the
first 2 years of life reduces the risk of the development of AE.32
Complementary therapy
Complementary therapies include Chinese herbal medicine,
herbal medicine, homeopathy, aromatherapy, massage therapy,
acupuncture, climatotherapy, and African traditional medicine.
Studies have failed to show any convincing benefit with
Chinese herbal medicine and aromatherapy. A worsening of
the eczema was noted with prolonged aromatherapy.
There are few or no studies evaluating the safety and efficacy
of the other treatment modalities involving complementary
medicine.
The meetings of the Working Group were possible due to a
grant from Novartis.
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